That was Week with a capital W. Two major FDA approvals for sickle cell came through on Friday - Casgevy, the first-ever CRISPR-based gene editing therapy from Vertex and CRISPR Therapeutics, and bluebird bio’s Lyfgenia, which comes with a hefty price tag and a black box warning. 

Axcella announced its closure; what does the future of long-covid treatments look like, especially as attention shifts to different markets like ADCs and neurological treatments? 

Also discussed - Vanda drops $100m on rights to MS drug Ponvory, AI regulatory developments in Europe. 

BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.